One of the most important things you can do to align healthcare strategies in the shift toward value-based care is to allow your clinicians to be part of that journey, explained Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services.
One of the most important things you can do to align healthcare strategies in the shift toward value-based care is to allow your clinicians to be part of that journey, explained Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services.
Transcript
What are some potential strategies for aligning incentives across the entire healthcare system during the shift to value-based care?
I think one of the most important things you can do to align healthcare strategies is to allow your clinicians to be part of that journey. Get your physicians, your nurses, your pharmacists, everybody involved upfront so they can recognize the connection to the care and they can help you understand what you should be doing. The other thing is to make sure your leaders are aligned. As you think about budgets and operating margins, everyone has to first think, “How am I going to give the best care to the patients at the most affordable costs?” If you can get your leaders aligned to that, then they’ll make choices that are aligned with what you want to do as an organization. I think leading with your clinicians and getting all your leaders on board so you’re all moving in the same direction. Keeping your patient or your member at the front is really how you get there.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More